EUVIMEDEUVIMED entdecken
Fallbericht

Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs

Georgios Evangelou, Ioannis Vamvakaris, Irene Konstantopoulou, Konstantinos Syrigos

ONCOLOGY · 2024

DOI: 10.46883/2024.25921024 ↗

Kurz gefasst

Fallbericht in der Zeitschrift ONCOLOGY, 2024. Verfasst von Georgios Evangelou und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Capecitabine, Temozolomide, Neoadjuvant Therapy, Lung Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant and adjuvant treatment in lung neuroendocrine tumors (NETs) is a field that has not been explored in-depth, with little information on the impact on disease-free survival. This case study highlights the effectiveness of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) in a woman with well-differentiated atypical carcinoid. The patient was asymptomatic at diagnosis and was referred to the outpatient NET clinic at Sotiria Hospital in Athens, following an incidental finding on a chest x-ray. 18F-fluorodeoxyglucose (FDG) PET/CT and 68Ga-Dotatoc PET/CT revealed another mass in the pancreas, with avidity in both imaging studies. The patient underwent treatment for 6 months with CAPTEM with a response in the lung NET and mediastinal lymph nodes. However, the mass in the pancreas slightly increased and was removed with a central pancreatectomy. The patient continued treatment with CAPTEM for 6 more months. There was further response according to RECIST 1.1 criteria (partial response in the mediastinal lymph nodes and a 21% regression in the primary tumor size). Pathology report after lobectomy with lymph node dissection showed a pathologic complete response in the mediastinal lymph nodes. Twenty-four months after surgery, the patient remains disease-free and has a good quality of life. Although large clinical trials are needed, this case study underlines the value of preoperative chemotherapy in atypical carcinoids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineTemozolomideNeoadjuvant TherapyLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedNeuroendocrine TumorsPositron Emission Tomography Computed Tomography

Substanzen

CapecitabineTemozolomide

Zitieren

APA

Evangelou, G., Vamvakaris, I., Konstantopoulou, I., & Syrigos, K. (2024). Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs. ONCOLOGY. https://doi.org/10.46883/2024.25921024

Vancouver

Evangelou G, Vamvakaris I, Konstantopoulou I, Syrigos K. Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs. ONCOLOGY. 2024. doi:10.46883/2024.25921024

BibTeX
@article{Evangelou2024,
  author = {Evangelou, Georgios and Vamvakaris, Ioannis and Konstantopoulou, Irene and Syrigos, Konstantinos},
  title = {Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs},
  journal = {ONCOLOGY},
  year = {2024},
  doi = {10.46883/2024.25921024}
}
Kostenlos starten →